NZ201130A - Iodine-125 or-131 labelled stilbene 4-0-monocarboxypropyl compounds and use for radioimmunological dosing:antigens - Google Patents
Iodine-125 or-131 labelled stilbene 4-0-monocarboxypropyl compounds and use for radioimmunological dosing:antigensInfo
- Publication number
- NZ201130A NZ201130A NZ201130A NZ20113082A NZ201130A NZ 201130 A NZ201130 A NZ 201130A NZ 201130 A NZ201130 A NZ 201130A NZ 20113082 A NZ20113082 A NZ 20113082A NZ 201130 A NZ201130 A NZ 201130A
- Authority
- NZ
- New Zealand
- Prior art keywords
- formula
- compound
- hexestrol
- monocarboxypropyl
- iodine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 50
- 239000000427 antigen Substances 0.000 title claims description 28
- 102000036639 antigens Human genes 0.000 title claims description 28
- 108091007433 antigens Proteins 0.000 title claims description 28
- 235000021286 stilbenes Nutrition 0.000 title claims description 12
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 title claims description 9
- 229940044173 iodine-125 Drugs 0.000 title claims description 6
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 title claims description 5
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 title 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 title 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 37
- PBBGSZCBWVPOOL-HDICACEKSA-N 4-[(1r,2s)-1-ethyl-2-(4-hydroxyphenyl)butyl]phenol Chemical compound C1([C@H](CC)[C@H](CC)C=2C=CC(O)=CC=2)=CC=C(O)C=C1 PBBGSZCBWVPOOL-HDICACEKSA-N 0.000 claims description 34
- 229950001996 hexestrol Drugs 0.000 claims description 32
- NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 claims description 27
- 229960003839 dienestrol Drugs 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 22
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 20
- 229910052740 iodine Inorganic materials 0.000 claims description 20
- 229960001340 histamine Drugs 0.000 claims description 19
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 18
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 18
- 229940098773 bovine serum albumin Drugs 0.000 claims description 18
- 239000011630 iodine Substances 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 13
- 230000003213 activating effect Effects 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 claims description 11
- 229960000452 diethylstilbestrol Drugs 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 150000008064 anhydrides Chemical class 0.000 claims description 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 150000001412 amines Chemical class 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 claims description 6
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 claims description 6
- AVMSWPWPYJVYKY-UHFFFAOYSA-N 2-Methylpropyl formate Chemical compound CC(C)COC=O AVMSWPWPYJVYKY-UHFFFAOYSA-N 0.000 claims description 5
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical group CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 5
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000002285 radioactive effect Effects 0.000 claims description 5
- -1 stilbene compound Chemical class 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 229960002885 histidine Drugs 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 229960003732 tyramine Drugs 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 229960004441 tyrosine Drugs 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000000243 solution Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 150000001629 stilbenes Chemical class 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- AXDLCFOOGCNDST-VIFPVBQESA-M Methyltyrosinate Chemical compound CN[C@H](C([O-])=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-VIFPVBQESA-M 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- XIMFCGSNSKXPBO-UHFFFAOYSA-N ethyl 2-bromobutanoate Chemical compound CCOC(=O)C(Br)CC XIMFCGSNSKXPBO-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- VNWKTOKETHGBQD-AKLPVKDBSA-N carbane Chemical group [15CH4] VNWKTOKETHGBQD-AKLPVKDBSA-N 0.000 description 1
- OKTJSMMVPCPJKN-YPZZEJLDSA-N carbon-10 atom Chemical group [10C] OKTJSMMVPCPJKN-YPZZEJLDSA-N 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8112934A FR2508905B1 (OSRAM) | 1981-07-01 | 1981-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ201130A true NZ201130A (en) | 1985-08-30 |
Family
ID=9260076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ201130A NZ201130A (en) | 1981-07-01 | 1982-07-01 | Iodine-125 or-131 labelled stilbene 4-0-monocarboxypropyl compounds and use for radioimmunological dosing:antigens |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4529713A (OSRAM) |
| EP (2) | EP0069018B1 (OSRAM) |
| AR (1) | AR244205A1 (OSRAM) |
| AT (1) | ATE18214T1 (OSRAM) |
| AU (3) | AU558848B2 (OSRAM) |
| CA (1) | CA1207775A (OSRAM) |
| DE (1) | DE3269359D1 (OSRAM) |
| DK (1) | DK165368C (OSRAM) |
| FR (1) | FR2508905B1 (OSRAM) |
| IE (1) | IE54489B1 (OSRAM) |
| NZ (1) | NZ201130A (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3572177D1 (de) * | 1984-10-19 | 1989-09-14 | Nihon Mediphysics Co Ltd | Imunoassay for estriol-3-sulfate |
| DE3674575D1 (de) * | 1985-12-27 | 1990-10-31 | Daicel Chem | Verwendung von optisch-aktiven carboalkylierten aminoalkohole zur trennung von optischen isomeren. |
| DE4326465A1 (de) * | 1993-01-20 | 1995-02-09 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4310675A (en) * | 1976-09-29 | 1982-01-12 | Becton Dickinson & Company | Monoradioiodinated imidazole derivatives |
| DE3572177D1 (de) * | 1984-10-19 | 1989-09-14 | Nihon Mediphysics Co Ltd | Imunoassay for estriol-3-sulfate |
| ATE89567T1 (de) * | 1985-11-12 | 1993-06-15 | Wallone Region | Konjugate von vinblastin und seine derivate, verfahren zur herstellung derselben und diese konjugate enthaltende pharmazeutische zusammensetzungen. |
| EP0250358A3 (en) * | 1986-06-20 | 1988-10-05 | Schering Aktiengesellschaft | Novel complex compounds |
-
1981
- 1981-07-01 FR FR8112934A patent/FR2508905B1/fr not_active Expired
-
1982
- 1982-06-22 US US06/390,938 patent/US4529713A/en not_active Expired - Fee Related
- 1982-06-28 AT AT82401188T patent/ATE18214T1/de not_active IP Right Cessation
- 1982-06-28 EP EP82401188A patent/EP0069018B1/fr not_active Expired
- 1982-06-28 EP EP84201524A patent/EP0154045A3/fr not_active Withdrawn
- 1982-06-28 DE DE8282401188T patent/DE3269359D1/de not_active Expired
- 1982-06-30 AU AU85488/82A patent/AU558848B2/en not_active Ceased
- 1982-06-30 CA CA000406423A patent/CA1207775A/fr not_active Expired
- 1982-06-30 IE IE1591/82A patent/IE54489B1/en not_active IP Right Cessation
- 1982-06-30 DK DK294082A patent/DK165368C/da not_active IP Right Cessation
- 1982-07-01 NZ NZ201130A patent/NZ201130A/en unknown
-
1984
- 1984-01-18 AR AR84295461A patent/AR244205A1/es active
-
1986
- 1986-10-06 AU AU63535/86A patent/AU579751B2/en not_active Ceased
- 1986-10-06 AU AU63536/86A patent/AU599603B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| FR2508905B1 (OSRAM) | 1984-01-27 |
| AU8548882A (en) | 1983-01-06 |
| AU6353686A (en) | 1987-01-08 |
| EP0154045A2 (fr) | 1985-09-11 |
| EP0154045A3 (fr) | 1986-02-05 |
| EP0069018B1 (fr) | 1986-02-26 |
| AU558848B2 (en) | 1987-02-12 |
| DE3269359D1 (en) | 1986-04-03 |
| AU579751B2 (en) | 1988-12-08 |
| ATE18214T1 (de) | 1986-03-15 |
| AU599603B2 (en) | 1990-07-26 |
| EP0069018A3 (en) | 1983-02-09 |
| IE54489B1 (en) | 1989-10-25 |
| AU6353586A (en) | 1987-01-08 |
| AR244205A1 (es) | 1993-10-29 |
| DK165368C (da) | 1993-04-05 |
| DK294082A (da) | 1983-01-02 |
| IE821591L (en) | 1983-01-01 |
| DK165368B (da) | 1992-11-16 |
| EP0069018A2 (fr) | 1983-01-05 |
| FR2508905A1 (OSRAM) | 1983-01-07 |
| US4529713A (en) | 1985-07-16 |
| CA1207775A (fr) | 1986-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1341053C (en) | Polypeptide and protein derivatives and process for their preparation | |
| JPS624368B2 (OSRAM) | ||
| Mullen et al. | A new fluoridolyzable anchoring linkage for orthogonal solid-phase peptide synthesis: design, preparation, and application of the N-(3 or 4)-[[4-(hydroxymethyl) phenoxy]-tert-butylphenylsilyl] phenyl pentanedioic acid monoamide (Pbs) handle | |
| US5869606A (en) | Amino acids peptides or derivatives thereof coupled to fats | |
| JPH01230591A (ja) | Ｔ―抗原決定基を有する人工抗原 | |
| JPS62175497A (ja) | 胆汁酸誘導体およびその製造法 | |
| US4122078A (en) | Antigens and antibodies of catecholamines | |
| Levy | Preparation of photo-affinity probes for the insulin receptor site in adipose and liver cell membranes | |
| US4639336A (en) | Novel radioactive estradienes labelled with iodine | |
| Wellner et al. | Synthesis of a C‐Glycoside Analogue of β‐d‐Galactosyl Hydroxynorvaline and Its Use in Immunological Studies | |
| AU2001287832C1 (en) | Method for binding, in solution, a peptide and a lipophilic vector and uses thereof | |
| GB1562734A (en) | N - acetylmuramyl - d - alanyl - d - isoglutamine | |
| JP4120846B2 (ja) | 活性化ペプチド類および接合体 | |
| US4820860A (en) | Novel thyronine derivatives | |
| AU599603B2 (en) | Process for preparation of antigens using radio active stilbene derivatives labelled with iodine and the antigens obtained | |
| CA2415425A1 (en) | Insulin derivatives and synthesis thereof | |
| EP0073834B1 (en) | Water-soluble cholesterol derivatives | |
| US4895872A (en) | Immunosupressive analogues and derivatives of succinylacetone | |
| US4202873A (en) | Alkylolamides of iodizable amino acids and immune test reagents containing them | |
| US4436828A (en) | Reactive asymmetrical dicarboxylic acid esters and reagents for the investigation of cardiac glycosides | |
| NZ206564A (en) | 4,9,11-estratrien-3-methyloximes and antigens | |
| JPH0414120B2 (OSRAM) | ||
| JP2782232B2 (ja) | プロテアーゼ阻害剤 | |
| WO2008089485A2 (en) | Carboxyethylpyrrole compounds and methods of their production | |
| Brunel et al. | Synthesis and applications of alkylated C-sugars as peptide bioconjugates |